Does human βA4 exert a protective function against oxidative stress in Alzheimer's disease?

Medical Hypotheses

Volumn 54, Issue 4, 2000, Pages 672-677

  Berthon, G ^a  

^a UNIVERSITÉ DE TOULOUSE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID A PROTEIN; COPPER ION; OXYGEN; AMYLOID; AMYLOID BETA PROTEIN;

ALZHEIMER DISEASE; BIOLOGICAL MODEL; CELL PH; HUMAN; IMMUNE RESPONSE; NEUROLOGIC DISEASE; OXIDATION; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN DEGRADATION; PROTEIN SECRETION; REVIEW; THEORY; BIOSYNTHESIS; BRAIN; DRUG ANTAGONISM; PATHOPHYSIOLOGY; PHYSIOLOGY;

ALZHEIMER DISEASE; AMYLOID; AMYLOID BETA-PROTEIN; BRAIN; HUMANS; OXIDATIVE STRESS;

EID: 0033623811     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1054/mehy.1999.0924     Document Type: Article

References (78)

1. Mera S. L. Aluminium, amyloid, and Alzheimer's disease. Med Lab Sci. 48:1991;283-295.
2. Maggio J. E., Stimson E. R., Ghilardi J. R. Reversible in vitro growth of Alzheimer disease β-amyloid plaques by deposition of labeled amyloid peptide. Proc Natl Acad Sci USA. 89:1992;5462-5466.
3. Rowan M. R. Recent research on the causes of Alzheimer's disease. Proc Nutr Soc. 52:1993;255-262.
4. Storey E., Masters C. L. Amyloid, aluminium and the aetiology of Alzheimer's disease. Med J Aust. 163:1995;256-259.
5. Crapper McLachlan D. R. Would decreased aluminium ingestion reduce the incidence of Alzheimer's disease? Can Med Assn J. 147:1992;846.
6. Sheng J. G., Zhou X. Q., Mrak R. E., Griffin W. S. T. Progressive neuronal injury associated with amyloid plaque formation in Alzheimer disease. J Neuropathol Exp Neurol. 57:1998;714-717.
7. Mann D. M. A. Association between Alzheimer disease and Down syndrome: neuropathological observations. Berg J. M., Karlinsky H., Hollan A. J. Alzheimer disease, Down syndrome, and their relationship. 1993;71-92 Oxford University Press, Oxford.
8. Spillantini M. G., Goedert M. Tau protein pathology in neurodegenerative diseases. Trends Neurosci. 21:1998;428-433.
9. 27AI NMR investigation. J Protein Chem. 14:1995;633-644.
10. Dyrks T., Dyrks E., Hartmann T., Masters C., Beyreuther K. Amyloidogenicity of βA4 and βA4-bearing amyloid protein precursor fragments by metal-catalyzed oxidation. J Biol Chem. 267:1992;18210-18217.
11. Yankner B. A., Duffy L. K., Kirschner D. A. Neurotrophic and neurotoxic effects of amyloid β protein: reversal by tachykinin neuropeptides. Science. 250:1990;279-282.
12. Pike C. J., Walencewicz A. J., Glabe C. G., Cotman C. W. In vitro aging of β-amyloid protein causes peptide aggregation and neurotoxicity. Brain Res. 562:1991;311-314.
13. Kawahara M., Muramoto K., Kobayashi K., Mori H., Kuroda Y. Aluminum promotes the aggregation of Alzheimer's amyloid β-protein in vitro. Biochem Biophys Res Commun. 198:1994;531-535.
14. Vyas S. B., Duffy L. K. Stabilization of secondary structure of Alzheimer β-protein by aluminum(III) ions and D-Asp substitutions. Biochem Biophys Res Commun. 206:1995;718-723.
15. Atwood C. S., Moir R. D., Huang X. Dramatic aggregation of Alzheimer Aβ by Cu(II) is induced by conditions representing physiological acidosis. J Biol Chem. 273:1998;12817-12826.
16. Dyrks T., Dyrks E., Masters C. L., Beyreuther K. Amyloidogenicity of rodent and human βA4 sequences. FEBS Lett. 324:1993;231-236.
17. Roberts G. W., Gentleman S. M., Lynch A., Graham D. I. βA4 amyloid protein deposition in brain after head trauma. Lancet. 338:1991;1422-1423.
18. Pierce J. E. S., Trojanowski J. Q., Graham D. I., Smith D. H., McIntosh T. K. Immunohistochemical characterization of alterations in the distribution of amyloid precursor proteins and β-amyloid peptide after experimental brain injury in the rat. J Neurosci. 16:1996;1083-1090.
19. Hock C., Golombowski S., Müller-Spahn F. Cerebrospinal fluid levels of amyloid precursor protein and amyloid β peptide in Alzheimer's disease and major depression - Inverse correlation with dementia severity. Eur Neurol. 39:1998;111-118.
20. Palmer A. M., Burns M. A. Selective increase in lipid peroxidation in the inferior temporal cortex in Alzheimer's disease. Brain Res. 645:1994;333-342.
21. Smith M. A., Perry G. Free radical damage, iron and Alzheimer's disease. J Neurol Sci. 134:1995;92-94.
22. Smith C. D., Carney J. M., Starke-Reed P. E. Excess brain protein oxidation and enzyme dysfunction in normal aging and in Alzheimer disease. Proc Nat Acad Sci USA. 88:1991;10540-10543.
23. Behl C. Amyloidβ-protein toxicity and oxidative stress in Alzheimer's disease. Cell Tissue Res. 290:1997;471-480.
24. Verbeek M. M., Ruiter D. J., de Waal R. M. W. The role of amyloid in the pathogenesis of Alzheimer's disease. Biol Chem. 378:1997;937-950.
25. Netland E. E., Newton J. L., Majocha R. E., Tate B. A. Indomethacin reverses the microglial response to amyloid β-protein. Neurobiol Aging. 19:1998;201-204.
26. Subbarao K. V., Richardson J. S., Ang L. C. Autopsy samples of Alzheimer's cortex show increased peroxidation in vitro. J Neurochem. 55:1990;342-345.
27. Barrow C. J., Zagorski M. G. Solution structures of β peptide and its constituent fragments: relations to amyloid deposition. Science. 253:1991;179-182.
28. Shinobu L. A., Beal M. F. The role of oxidative processes and metal ions in aging and Alzheimer's disease. Connor J. R. Metals and oxidative damage in neurological disorders. 1997;237-275 Plenum Press, New York.
29. Behl C., Davis J. B., Lesley R., Schubert D. Hydrogen peroxide mediates amyloid β protein toxicity. Cell. 77:1994;817-827.
30. Smith M. A., Hirai K., Hsiao K. Amyloidβ deposition in Alzheimer transgenic mice is associated with oxidative stress. J Neurochem. 70:1998;2212-2215.
31. Smith M. A., Harris P. L. R., Sayre L. M., Perry G. Iron accumulation in Alzheimer's disease is a source of redox-generated free radicals. Proc Natl Acad Sci USA. 94:1997;9866-9868.
32. Connor J. R., Snyder B. S., Beard J. L., Fine R. E., Mufson E. F. Regional distribution of iron and iron-regulatory proteins in the brain in aging and Alzheimer's disease. J Neurosci Res. 31:1992;327-335.
33. Smith M. A., Wehr K., Harris P. L. R., Siedlack S. L., Connor J. R., Perry G. Abnormal localization of iron regulatory protein in Alzheimer's disease. Brain Res. 788:1998;232-236.
34. Cornett C. R., Markesbery W. R., Ehmann W. D. Imbalance of trace elements related to oxidative damage in Alzheimer's disease brain. Neurotoxicology. 19:1998;339-346.
35. Deibel M. A., Ehmann W. D., Markesbery W. R. Copper, iron and zinc imbalances in severely degenerated brain regions in Alzheimer's disease: possible relation to oxidative stress. J Neurol Sci. 143:1996;137-142.
36. Yan S. D., Chen X., Fu J. RAGE and amyloid-β peptide neurotoxicity in Alzheimer's disease. Nature. 382:1996;685-691.
37. Hensley K., Carney J. M., Mattson M. P. A model for β-amyloid aggregation and neurotoxicity based on free radical generation by the peptide: relevance to Alzheimer's disease. Proc Natl Acad Sci USA. 91:1994;3270-3274.
38. Harris M. E., Hensley K., Butterfield D. A., Leedle R. A., Carney J. M. Direct evidence of oxidative injury produced by the Alzheimer's β-amyloid peptide (1-40) in cultured hippocampal neurons. Exp Neurol. 131:1995;193-202.
39. Markesbery W. R. Oxidative stress hypothesis in Alzheimer's disease. Free Rad Biol Med. 23:1997;134-147.
40. Iwatsubo T., Odaka A., Suzuki N., Mizusawa H., Nukina N., Ihara Y. Visualization of Aβ42 (43) and Aβ40 in senile plaques with end-specific Aβ monoclonals: evidence that an initially deposited species is Aβ42 (43). Neuron. 13:1994;45-53.
41. Jarrett J. T., Berger E. P., Lansbury P. T. Jr. The carboxy terminus of the β amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease. Biochemistry. 32:1993;4693-4697.
42. Hilbich C., Kister-Woike B., Reed J., Masters C. L., Beyreuther K. Aggregation and secondary structure of synthetic amyloid βA4 peptides of Alzheimer's disease. J Mol Biol. 218:1991;149-163.
43. 717) mutants. Science. 264:1994;1336-1340.
44. Butterfield D. A., Hensley K., Harris M., Mattson M., Carney J. βamyloid peptide free radical fragments initiate synaptosomal lipoperoxidation in a sequence-specific fashion: implications to Alzheimer's disease. Biochem Biophys Res Commun. 200:1994;710-715.
45. Storey E., Masters C. L. Amyloid aluminium and the aetiology of Alzheimer's disease (reply). Med J Austr. 164:1996;253.
46. Younkin S. G. Evidence that Aβ42 is the real culprit in Alzheimer's disease. Ann Neurol. 37:1995;287-288.
47. Sudoh S., Kawamura Y., Sato K. Presenilin 1 mutations linked to familial Alzheimer's disease increase the intracellular levels of amyloid β-protein 1-42 and its n-terminally truncated variant(s) which are generated at distinct sites. J Neurochem. 71:1998;1535-1543.
48. Mehta P. D., Dalton A. J., Mehta S. P., Kim K. S., Sersen E. A., Wisniewski H. M. Increased plasma amyloid β protein 1-42 levels in Down syndrome. Neurosci Lett. 241:1998;13-16.
49. 2. Arch Biochem Biophys. 335:1997;381-387.
50. Davies K. J. A., Delsignore M. E., Lin S. W. Protein damage and degradation by oxygen radicals II. Modification of amino acids. J Biol Chem. 262:1987;9902-9907.
51. Huang X., Atwood C. S., Moir R. D. Zinc-induced Alzheimer's Aβ1-40 aggregation is mediated by conformational factors. J Biol Chem. 272:1997;26464-26470.
52. Berthon G., Dousset N. Al(III)-citrate interactions aggravate Fe(II)-induced peroxidation of brain model membranes. Potential implications for the pathogenesis of Alzheimer's disease. Redox Report. 2:1996;412.
53. Xie C. X., Yokel R. A. Aluminium facilitation of iron-mediated lipid peroxidation is dependent on substrate, pH, and aluminium and iron concentrations. Arch Biochem Biophys. 327:1996;222-226.
54. Miche H., Brumas V., Berthon G. Copper(II) interactions with nonsteroidal antiinflammatory agents. II - Anthranilic acid as a potential OH-inactivating ligand. J Inorg Biochem. 68:1997;27-38.
55. Gutteridge G. M. C., Quinlan G. J., Clark I., Halliwell B. Aluminium salts accelerate peroxidation of membrane lipids stimulated by iron salts. Biochim Biophys Acta. 835:1985;441-447.
56. Etherington D. J., Pugh G., Silver I. A. Collagen degradation in an experimental inflammatory lesion: studies on the role of the macrophage. Acta Biol Med Germ. 40:1981;1625-1631.
57. Geigy Scientific Tables. Basel, Switzerland, Ciba-Geigy Limited, 1981, 159.
58. Sorenson J. R. J. The anti-inflammatory activities of copper complexes. Sigel H. Metal Ions in Biological Systems. 1982;77-124 Marcel Dekker Inc, New York.
59. Sorenson J. R. J., Kishore V. Antirheumatic activity of copper complexes. Trace Elem Med. 1:1984;93-102.
60. Milanino R., Cassini A., Conforti A. Copper and zinc status during acute inflammation: studies on blood, liver and kidneys metal levels in normal and inflamed rats. Agents Actions. 19:1986;215-223.
61. Milanino R., Marrella M., Moretti U., Concari E., Velo G. P. Copper and zinc status in rats with acute inflammation: focus on the inflamed area. Agents Actions. 24:1988;356-364.
62. Kishore V. Effect of adjuvant arthritis on copper, zinc and iron metabolism in the rat. Res Commun Chem Pathol Pharm. 63:1989;153-156.
63. Dore-Duffy P., Peterson M., Catalanotto F. Zinc profiles in rheumatoid arthritis. Clin Exp Rheumatol. 8:1990;541-546.
64. Powanda M. C. The role of leucocyte endogenous mediator (endogenous pyrogen). Sorenson J. R. J. Inflammatory Diseases and Copper. 1982;31-43 The Humana Press, Clifton, New Jersey.
65. Li Q. X., Whyte S., Tanner J. E., Evin G., Beyreuther K., Masters C. L. Secretion of Alzheimer's disease Aβ amyloid peptide by activated human platelets. Lab Invest. 78:1998;461-469.
66. Halliwell B., Gutteridge J. M. C. Oxygen toxicity, oxygen radicals, transition metals and disease. Biochem J. 219:1984;1-14.
67. McCord J. M. Free radicals and inflammation: protection of synovial fluid by superoxide dismutase. Science. 185:1974;529-530.
68. Gutteridge J. M. C. Free radical formation and antioxidant protection in extracellular fluids. Crastes de Paulet A. Free Radicals, Lipoproteins, and Membrane Lipids. 1990;371-379 Plenum Press, New York.
69. May P. M., Linder P. W., Williams D. R. Computer simulation of metal-ion equilibria in biofluids: models for the low-molecular-weight complex distribution of calcium(II), magnesium(II), manganese(II), iron(III), copper(II), zinc(II), and lead(II) ions in human blood plasma. J Chem Soc Dalton Trans. 1977;588-595.
70. Berthon G. Is copper pro- or anti-inflammatory? A reconciling view and a novel approach for the use of copper in the control of inflammation. Agents Actions. 39:1993;210-217.
71. Rowley D. A., Halliwell B. Superoxide-dependent and ascorbate-dependent formation of hydroxyl radicals in the presence of copper salts: a physiologically significant reaction? Arch Biochem Biophys. 225:1983;279-284.
72. Sorenson J. R. J., Kishore V., Pezeshk A., Oberley L. W., Leuthauser S. W. C., Oberley T. D. Copper complexes: a physiological approach to the treatment of 'Inflammatory diseases'. Inorg. Chim. Acta. 91:1984;285-294.
73. Frautschy S. A., Horn D. L., Sigel J. J. Protease inhibitor coinfusion with amyloid β-protein results in enhanced deposition and toxicity in rat brain. J Neurosci. 18:1998;8311-8321.
74. Mantyh P. W., Ghilardi J. R., Rogers S. Aluminium, iron, and zinc ions promote aggregation of physiological concentrations of β-amyloid peptide. J Neurochem. 61:1993;1171-1174.
75. Martin R. B. The chemistry of aluminium as related to biology and medicine. Clin Chem. 32:1986;1797-1806.
76. Berthon G. Chemical speciation studies in relation to aluminium metabolism and toxicity. Coord Chem Rev. 149:1996;241-280.
77. Rondeau V., Commenges D., Jacqmin-Gadda, Dartigues J. F. Relation between aluminium and silica concentrations in drinking water and the risk of Alzheimer's disease. Neurobiol Aging. 19:1998;30.
78. McLachlan D. R., Lukiw W. J., Kruch T. P. A. Aluminum and Alzheimer's disease. Berthon G. Handbook of Metal-Ligand Interactions in Biological Fluids; Bioinorganic Medicine, 1995;935-944 Marcel Dekker Inc, New York.